Your shopping cart is currently empty

L524-0366 ([1-(3-chlorophenyl)triazol-4-yl]-thiomorpholino-methanone) is a TWEAK-Fn14 signaling cascade inhibitor.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $113 | In Stock | In Stock | |
| 5 mg | $247 | In Stock | In Stock | |
| 10 mg | $378 | In Stock | In Stock | |
| 25 mg | $653 | In Stock | In Stock | |
| 50 mg | $892 | In Stock | In Stock | |
| 100 mg | $1,180 | In Stock | In Stock | |
| 200 mg | $1,620 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $255 | In Stock | In Stock |
| Description | L524-0366 ([1-(3-chlorophenyl)triazol-4-yl]-thiomorpholino-methanone) is a TWEAK-Fn14 signaling cascade inhibitor. |
| Targets&IC50 | sTWEAK:7.8 µM |
| In vitro | L524-0366 mitigated maladaptive remodeling with TAC. TWEAK induced secretion of the pro-inflammatory chemokine, monocyte chemoattractant protein 1 from WT but not Fn14-/-?fibroblasts in vitro, in part through activation of non-canonical NF-κB signaling. Finally, Fn14 expression was increased in mouse following TAC and in human failing hearts. |
| Cell Research | Wild type (WT) and Fn14 knock out (Fn14-/-) mice were subjected to pressure overload [transaortic constriction (TAC)] for 1 or 6 weeks. A subset of WT TAC animals were treated with the Fn14 antagonist L524-0366. Cardiac function was measured by echocardiography. Cardiac fibrosis and macrophage infiltration were quantified using immunohistochemistry and flow cytometry, respectively. Cardiac fibroblasts were isolated for quantifying TWEAK-induced chemokine release. |
| Synonyms | [1-(3-chlorophenyl)triazol-4-yl]-thiomorpholino-methanone |
| Molecular Weight | 308.79 |
| Formula | C13H13ClN4OS |
| Cas No. | 951612-19-4 |
| Smiles | C(=O)(C1=CN(N=N1)C2=CC(Cl)=CC=C2)N3CCSCC3 |
| Relative Density. | no data available |
| Storage | keep away from direct sunlight | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 25 mg/mL (80.96 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 5% DMSO+95% Corn oil: 1 mg/mL (3.24 mM), Suspension. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.